

Report

SARS-CoV-2 infections elicit higher levels of original antigenic sin antibodies compared to SARS-CoV-2 mRNA vaccinations

Elizabeth M. Anderson¹, Theresa Eilola¹, Eileen Goodwin¹, Marcus J. Bolton¹, Sigrid Gouma¹, Rishi R. Goel^{2,3,4}, Mark M. Painter^{2,3,4}, Sokratis A. Apostolidis^{2,3,5}, Divij Mathew^{2,3,4}, Debora Dunbar⁶, Danielle Fiore⁷, Amanda Brock⁸, JoEllen Weaver⁸, John S. Millar⁹, Stephanie DerOhannessian^{8,9}, The UPenn COVID Processing Unit¹⁰, Allison R. Greenplate^{2,3}, Ian Frank⁶, Daniel J. Rader^{8,9}, E. John Wherry^{2,3,4,11}, Scott E. Hensley^{1,2*}

¹Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

²Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

³Immune Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

⁴Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania, Philadelphia, PA 19104, USA

⁵Division of Rheumatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

⁶Division of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

⁷Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

⁸Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA


⁹Department of Genetics and Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

¹⁰The UPenn COVID Processing Unit is a unit of individuals from diverse laboratories at the University of Pennsylvania who volunteered time and effort to enable study of COVID-19 patients during the pandemic. Members are listed in the acknowledgement section.

¹¹Parker Institute for Cancer Immunotherapy, Perelman School of Medicine, University of Pennsylvania, PA 19104, USA

*Correspondence: hensley@pennmedicine.upenn.edu

Infected





Vaccinated




medRxiv preprint doi: <https://doi.org/10.1101/2021.09.30.21264363>; this version posted October 1, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).

SARS-CoV-2 spike antibodies

Subunit

-  S1
-  S2







1st dose

2nd dose

Back boosting of β -hCoV antibodies

hCoV Antibodies

-  SARS-CoV-2
-  OC43



1 **HIGHLIGHTS**

- 2 • SARS-CoV-2 mRNA vaccines elicit higher levels of antibodies compared to SARS-CoV-
3 2 infections
- 4 • The first dose of an mRNA vaccine generates both S1 and S2 responses while the second
5 dose boosts primarily S1-specific antibodies
- 6 • SARS-CoV-2 infections, but not mRNA vaccinations, elicit high levels of antibodies that
7 bind strongly to seasonal coronaviruses but weakly to SARS-CoV-2
- 8

9 **SUMMARY**

10 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccines elicit higher
11 levels of antibodies compared to natural SARS-CoV-2 infections in most individuals; however,
12 the specificities of antibodies elicited by vaccination versus infection remain incompletely
13 understood. Here, we characterized the magnitude and specificity of SARS-CoV-2 spike-reactive
14 antibodies from 10 acutely infected health care workers and 23 participants who received
15 mRNA-based SARS-CoV-2 vaccines. We found that infection and primary mRNA vaccination
16 elicited S1 and S2-reactive antibodies, while secondary vaccination boosted mostly S1
17 antibodies. Using magnetic bead-based absorption assays, we found that SARS-CoV-2 infections
18 elicited a large proportion of original antigenic sin-like antibodies that bound efficiently to
19 common seasonal human coronaviruses but poorly to SARS-CoV-2. In converse, vaccination
20 only modestly boosted antibodies reactive to common seasonal human coronaviruses and these
21 antibodies bound efficiently to SARS-CoV-2. Our data indicate that SARS-CoV-2 mRNA
22 vaccinations elicit fundamentally different antibody responses compared to SARS-CoV-2
23 infections.

24 **KEYWORDS**

25 SARS-CoV-2, antibodies, mRNA vaccines, original antigenic sin, coronavirus

26

27

28 BACKGROUND

29 Since late 2019 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
30 spread across the world causing a global pandemic^{1,2}. This prompted the rapid development of
31 several SARS-CoV-2 vaccines including two that use an mRNA-based platform (reviewed in³⁻⁵).
32 The mRNA vaccines, Pfizer BNT162b2 and Moderna mRNA-1273, employ lipid nanoparticles
33 that encase modified mRNA encoding the spike protein of SARS-CoV-2⁶. SARS-CoV-2 mRNA
34 vaccines have been found to be safe and effective at preventing severe COVID-19,
35 hospitalizations, and death^{7,8}. Recent studies demonstrate that SARS-CoV-2 mRNA vaccines elicit
36 long-lived antibody responses that partially recognize and protect against antigenically distinct
37 SARS-CoV-2 variants⁹⁻¹⁵.

38 Some studies suggest that prior infections with common seasonal human coronaviruses
39 (hCoVs) impact the severity of SARS-CoV-2 infections^{16,17}. Most individuals are exposed to
40 hCoVs early in childhood¹⁸⁻²³ and then re-exposed to antigenically drifted forms of these viruses
41 throughout life²⁴⁻²⁶. Common hCoVs include the HKU1 and OC43 betacoronaviruses (β -hCoVs)
42 and 229E and NL63 alphacoronaviruses²⁷⁻³⁰. Studies from our group and others have shown that
43 some individuals possessed antibodies that could bind to SARS-CoV-2 proteins prior to the
44 COVID-19 pandemic^{18,31,32}. SARS-CoV-2 is a β -hCoV, and antibodies reactive to the OC43 β -
45 hCoV can be boosted upon SARS-CoV-2 infections^{16,18,32,33} and SARS-CoV-2 mRNA
46 vaccinations³⁴⁻³⁶. It is unknown if the recall of β -hCoV antibodies upon SARS-CoV-2 infections
47 impacts disease outcome. A recent study suggests that the recall of OC43 β -hCoV antibodies is
48 associated with a compromised *de novo* SARS-CoV-2 response in individuals with fatal COVID-
49 19³⁷.

50 The boosting of hCoV antibodies upon infection with the antigenically distinct SARS-
51 CoV-2 is consistent with the doctrine of ‘original antigenic sin’, first proposed to describe
52 influenza virus antibody responses by Thomas Francis in 1960³⁸. We recently developed new
53 absorption assays to show that sequential heterosubtypic influenza virus infections elicit antibodies
54 that paradoxically do not bind effectively to the boosting viral strain³⁹. In the current report, we
55 used a similar absorption technique to define the specificity of β -hCoV antibodies elicited by
56 SARS-CoV-2 infections. We completed a series of studies to determine if these boosted β -hCoV
57 antibodies could cross-react to SARS-CoV-2 and we compared antibodies elicited by SARS-CoV-
58 2 infections and SARS-CoV-2 mRNA vaccinations.

59 RESULTS

60 SARS-CoV-2 infections and vaccinations elicit antibodies against the SARS-CoV-2 spike protein

61 We obtained samples from individuals before and after acute SARS-CoV-2 infections
62 (n=10) and pre-/post- two doses of a Pfizer BNT162b2 mRNA SARS-CoV-2 vaccine (n=23).
63 Samples from SARS-CoV-2 infected individuals were obtained from a health care worker sero-
64 monitoring study in which all infections were relatively mild¹⁶. All 10 individuals were
65 seronegative in the beginning of this study and acquired a PCR-confirmed SARS-CoV-2 infection
66 over the course of the study. Blood samples were collected from SARS-CoV-2 infected individuals
67 5-28 days (mean 17.9 days) after PCR-confirmed infections. Blood samples were collected from
68 SARS-CoV-2 mRNA vaccinated individuals⁴⁰ 7-15 days post-primary immunization (mean 14.2
69 days), the day of or day before the booster immunization (mean 21.2 days post-primary), and 7-12
70 days post-booster immunization (mean 7.5 days post-boost). Individuals in our infection and
71 vaccination studies had similar ages and both groups were predominantly female (**Supplemental**
72 **Table 1**).

73 Consistent with previous studies (reviewed in⁴¹), antibodies against the full-length spike
74 (FL-S) of SARS-CoV-2 increased following infection (**Figure 1A**) and vaccination (**Figure 1B**).
75 SARS-CoV-2 FL-S antibody levels were similar following infections and primary vaccinations,
76 and antibody levels were significantly boosted following the second dose of vaccine (**Figure 1B-**
77 **C**). The SARS-CoV-2 FL-S protein consists of two domains, the S1 domain which encompasses
78 the receptor binding domain (RBD) essential for cell attachment and entry⁴²⁻⁴⁵ and the N terminal
79 domain (NTD), and the S2 domain which shares more sequence homology with hCoVs^{28,33}.
80 Infection and primary vaccination elicited high levels of both S1 and S2 antibodies (**Figure 1A-**
81 **B**), whereas secondary vaccinations boosted S1 antibodies more efficiently compared to S2
82 antibodies (**Figure 1B, D-E**).

84 SARS-CoV-2 infections and vaccinations elicit antibodies against a common human 85 betacoronavirus

86 We previously found that antibodies against the FL-S of the OC43 β -hCoV are boosted
87 upon SARS-CoV-2 infection in hospitalized patients with severe disease¹⁸. Consistent with these
88 findings, we found that antibodies reactive to the OC43 FL-S increased upon SARS-CoV-2
89 infections in health care workers with mild disease (**Figure 2A**). A recent study showed that

90 antibody titers against β -hCoVs increase upon SARS-CoV-2 mRNA vaccination³⁶. Although we
91 found small increases in OC43 FL-S antibody titers following SARS-CoV-2 mRNA vaccinations
92 (**Figure 2B**), the magnitude of OC43 FL-S antibody boosts were much lower following
93 vaccinations compared to infections for most individuals (**Figure 2C**). Antibodies boosted by
94 infections and vaccinations primarily targeted the S2 domain of the OC43 spike (**Figure 2A-B**,
95 **2D-E**), with infections boosting S2 responses more effectively compared to vaccinations (**Figure**
96 **2E**). Booster vaccinations did not affect levels of OC43 FL-S, S1, or S2 antibody levels (**Figure**
97 **2B-E**).

98

99 *SARS-CoV-2 infections elicit higher levels of original antigenic sin antibodies compared to SARS-*
100 *CoV-2 mRNA vaccinations*

101 We previously developed absorption-based assays to measure the level of cross-reactivity
102 of antibodies elicited by influenza virus infections³⁹. In that study, we sequentially infected ferrets
103 with two antigenically distinct influenza virus strains and analyzed serum samples collected after
104 each infection. We found that many antibodies elicited by secondary influenza virus infections
105 paradoxically did not bind effectively to the secondary boosting influenza virus strain. We
106 proposed that antigenically distinct influenza viruses engage memory B cells elicited by prior
107 infections through multiple low affinity interactions with thousands of B cell receptors on memory
108 B cells. Low affinity antibodies secreted in a soluble form through this recall response fail to bind
109 to the antigenically distinct recall antigens because they require the level of multivalent binding
110 that is provided on B cells.

111 We developed a magnetic bead-based absorption assay to determine if OC43 FL-S
112 antibodies elicited by SARS-CoV-2 infection and vaccination cross-react with SARS-CoV-2 FL-
113 S. We incubated serum samples with beads coupled with either OC43 FL-S or SARS-CoV-2 FL-
114 S and then we depleted bead-reactive antibodies using a magnetic column. Then, we quantified
115 antibody levels in serum absorbed with antigen coupled beads to assess antibody cross-reactivity.
116 SARS-CoV-2 FL-S-reactive antibodies elicited by infection were efficiently depleted with SARS-
117 CoV-2 FL-S coupled beads but not OC43 FL-S coupled beads (**Figure 3A**). OC43 FL-S-reactive
118 antibodies boosted by SARS-CoV-2 infection were efficiently depleted with OC43 FL-S coupled
119 beads, but surprisingly these antibodies were not depleted with SARS-CoV-2 FL-S coupled beads
120 (**Figure 3B**). These results are surprising since these OC43 FL-S-reactive antibodies were boosted

121 upon SARS-CoV-2 infection. Vaccination-elicited antibodies had different cross-reactive
122 properties compared to infection-elicited antibodies. Similar to antibodies elicited by infection,
123 SARS-CoV-2 FL-S-reactive antibodies elicited by vaccination were efficiently depleted with
124 SARS-CoV-2 FL-S coupled beads but not OC43 FL-S coupled beads (**Figure 3D**). In contrast to
125 antibodies elicited by infection, OC43 FL-S-reactive antibodies boosted by SARS-CoV-2
126 vaccination were efficiently depleted with both OC43 FL-S and SARS-CoV-2 FL-S coupled beads
127 (**Figure 3B**). As a control, we quantified levels of influenza virus hemagglutinin (HA) antibodies
128 in these experiments and we found that HA-reactive antibodies were not depleted with SARS-
129 CoV-2 FL-S or OC43 FL-S labeled beads (**Figure 3C, 3F**). Taken together, our data suggest that
130 SARS-CoV-2 infection elicits OC43 FL-S-reactive antibodies that bind poorly to SARS-CoV-2
131 FL-S, while SARS-CoV-2 mRNA vaccinations elicits a relatively lower level of OC43 FL-S-
132 reactive antibodies that efficiently cross-react with both OC43 FL-S and SARS-CoV-2 FL-S.

133

134 **DISCUSSION**

135 Here we found that polyclonal antibodies elicited by SARS-CoV-2 mRNA vaccines are at
136 a higher magnitude and have different specificities compared to those elicited by SARS-CoV-2
137 infections. We demonstrate that primary vaccinations elicit antibodies that bind to the S1 and S2
138 region of SARS-CoV-2 spike, and that S1-specific antibody responses are preferentially boosted
139 after second vaccine doses. These data are consistent with recent reports that indicate that mRNA
140 vaccinations elicit broader and more diverse antibody responses that are more effective at
141 neutralizing SARS-CoV-2 variants compared to antibodies elicited by infection^{15,46-48,49}.

142 We found major differences in OC43 spike binding between antibodies elicited by SARS-
143 CoV-2 infections versus mRNA vaccinations. SARS-CoV-2 infections elicited high levels of
144 antibodies that bound to the S2 region of the OC43 spike protein; however, our absorption assays
145 demonstrated that these antibodies bound poorly to the SARS-CoV-2 spike. Conversely, we found
146 that SARS-CoV-2 mRNA vaccinations elicited lower levels of antibodies that reacted to the S2
147 region of the OC43 spike protein. Unlike antibodies elicited by infections, these vaccine-elicited
148 antibodies were truly cross-reactive and bound efficiently to both SARS-CoV-2 and OC43 spike
149 proteins. Further studies will be required to fully understand mechanisms that lead to different
150 types of antibody responses elicited by SARS-CoV-2 infections versus vaccinations. It is possible
151 that memory B cells elicited by prior β -hCoV infections are recalled by both SARS-CoV-2

152 infections and vaccinations, and that long-lived germinal centers elicited by mRNA vaccinations⁵⁰
153 are required to allow for somatic hypermutations that promote the formation of cross-reactive S2
154 antibodies that bind efficiently to the spike proteins of both β -hCoVs and SARS-CoV-2.
155 Consistent with this, a recent study found that S2-specific B cells with a memory phenotype are
156 quickly recruited following primary immunization of humans⁵¹

157 Boosting of OC43 S2-reactive antibodies following SARS-CoV-2 infection is consistent
158 with Thomas Francis' doctrine of 'original antigenic sin'³⁸. Francis found that antibodies elicited
159 by influenza vaccines often bound strongly to influenza virus strains that an individual was
160 exposed to in childhood, although it is not apparent if these recalled influenza virus antibody
161 responses typically occur at the expense of producing *de novo* antibodies (as we reviewed here⁵²)
162 The functional consequences of recalling low affinity S2-reactive antibodies following SARS-
163 CoV-2 infections are unclear. Our previous studies found no correlation between OC43-reactive
164 antibody induction and disease outcome following SARS-CoV-2 infection¹⁸ but a recent study
165 suggested that the recall of OC43-reactive antibodies is associated with a compromised *de novo*
166 SARS-CoV-2 response in individuals with fatal COVID-19³⁷. Further studies are required to
167 determine how the induction of different types of hCoV and SARS-CoV-2 antibodies affect
168 disease outcome following SARS-CoV-2 infections.

169

170

171

172 **STAR METHODS**

173 **KEY RESOURCES TABLE**

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Goat anti-human IgG-HRP	Jackson ImmunoResearch	109-036-098
mAb CR3022	Produced for this paper	N/A
mAb CR9114	Produced for this paper	N/A
Biological Samples		
Acutely SARS-CoV-2 infected HCW serum samples	The University of Pennsylvania	Gouma et al., 2021
SARS-CoV-2 mRNA vaccinated participants serum samples	The University of Pennsylvania	Goel et al., 2021
Chemicals, Peptides, and Recombinant Proteins		
SARS-CoV-2 spike protein	Produced for this paper	N/A
SARS-CoV-2 S1 subunit protein	ACROBiosystems	Cat. S1N-C52H3
SARS-CoV-2 S2 subunit protein	ACROBiosystems	Cat. S2N-C52H5
OC43 spike protein	Sino Biological	Cat. 40607-V08B
OC43 S1 subunit protein	Produced for this paper	N/A
OC43 S2 subunit protein	Produced for this paper	N/A
IVR-190 H1N1 rHA	Produced for this paper	N/A
Experimental Models: Cell Lines		
293T	ATCC	Cat. CRL-3216, RRID:CVCL_0063
293F	Laboratory of Scott Hensley, University of Pennsylvania, PA	Thermo Fisher cat. R79007
Recombinant DNA		
Plasmid: pCAGGS SARS-CoV-2 spike	Laboratory of Florian Krammer, Mt. Sinai, NY	Amanat et al., 2020
Plasmid: OC43 rS1	Laboratory of Scott Hensley, University of Pennsylvania, PA	Anderson et al., 2021
Plasmid: OC43 rS2	Laboratory of Scott Hensley, University of Pennsylvania, PA	Anderson et al. 2021
Plasmid: mAb CR3022 HC	Laboratory of Ian Wilson, Scripps Research Institute, CA	Yaun et al., 2020
Plasmid: mAb CR3022 LC	Laboratory of Ian Wilson, Scripps Research Institute, CA	Yaun et al., 2020
Plasmid: mAb CR9114 HC	Laboratory of Ian Wilson, Scripps Research Institute, CA	Dreyfus et al., 2012
Plasmid: mAb CR9114 LC	Laboratory of Ian Wilson, Scripps Research Institute, CA	Dreyfus et al., 2012
Software and Algorithms		
Prism8	GraphPad Software	www.graphpad.com/scientific-software/prism/

174

175 **RESOURCES AVAILABILITY**

176 **Lead Contact**

177 Further information and requests for resources and reagents should be directed to and will be
178 fulfilled by the Lead Contact, Scott E. Hensley (hensley@pennmedicine.upenn.edu).

179

180 **Materials Availability**

181 All unique reagents generated in this study will be available from the Lead Contact upon
182 reasonable request.

183

184 **Data and Code Availability**

185 All raw data generated in this study will be deposited on Mendeley Data:

186

187

188

189 **EXPERIMENTAL MODEL AND SUBJECT DETAILS**

190

191 **Samples from Human Subjects**

192 The infection cohort described in this report consists of health care workers within the
193 University of Pennsylvania Healthcare System who were recruited into a SARS-CoV-2 sero-
194 monitoring study that included biweekly blood draws as previously described¹⁶. A nasal
195 pharyngeal (NP) swab was collected from all health care workers who tested positive for SARS-
196 CoV-2 IgG and or IgM antibodies or who were experiencing COVID-like symptoms during the
197 study period. NP swabs were PCR tested for the presence of SARS-CoV-2 viral RNA.
198 Seroconverted health care workers with PCR-confirmed SARS-CoV-2 infection (n=10 adults \geq 18
199 years old) were included in this analysis.

200 The vaccination cohort described in this report consists of participants (n=23 adults \geq 18
201 years old) who enrolled in a study at the University of Pennsylvania that included blood draws
202 before and after two vaccination doses with an mRNA-based COVID-19 vaccine as previously
203 described⁴⁰. Whole blood was collected from participants who provided proof of vaccination with
204 Pfizer (BNT162b2) mRNA vaccines. Samples were collected at 4 timepoints: 1-2 weeks before
205 vaccination (baseline) (visit 1; V1), 1-2 weeks post-primary immunization (visit 2; V2), the day
206 of or day before booster immunization (visit 3; V3), and 1-2 weeks post-booster immunization

207 (visit 4; V4). Only participants without prior SARS-CoV-2 exposure were included in this report.
208 Plasma and PBMCs were isolated from whole blood for downstream assays.

209 All sera and plasma samples were heat-inactivated in a 56°C water bath for 1 hour prior to
210 serological testing. All samples were collected after obtaining informed consent and studies were
211 approved by the University of Pennsylvania Institutional Review Board.

212

213 **Cell lines**

214 293F cells were from Thermo fisher (Thermo Fisher cat. R79007). 293T cells were from
215 ATCC (ATCC cat. CRL-3216, RRID:CVCL_0063). All cell lines were cultured using
216 manufacturer's guidelines and used as described in Method Details below.

217

218 **METHOD DETAILS**

219 **Proteins for serological studies**

220 SARS-CoV-2 full length spike (FL-S) protein was purified by Ni-NTA resin from 293F
221 cells transfected with a plasmid that encodes the FL-S (A gift from Florian Krammer, Icahn School
222 of Medicine at Mt. Sinai, New York City NY)⁵³. S1 and S2 subunits of the SARS-CoV-2 spike
223 were purchased from Acro Biosystems (ACROBiosystems, Newark, DE; cat. S1N-C52H3, and
224 S2N-C52H5, respectively) and reconstituted in 200 µL Dulbecco's phosphate buffered saline
225 (DPBS) to a final concentration of 500 µg/mL. OC43 FL-S was also purchased (Sino Biological,
226 Wayne PA; cat. 40588-V08B) and reconstituted in DPBS. OC43 subunit proteins were purified in
227 our laboratory as previously described¹⁸. Briefly, mammalian expression plasmids encoding the
228 S1 (amino acids 15-760) or S2 (amino acids 766-1305) domains of the OC43 spike protein were
229 cloned with an N-terminal OC43 S signal peptide, and a C-terminus encoding a Factor Xa cleavage
230 site, a trimerization domain from T4 fibritin (Foldon), a site-specific biotinylation sequence
231 (AviTag), and a hexa-histidine purification tag. 293F cells were transfected with S1 or S2 encoding
232 plasmids and proteins were purified from cell culture supernatant 6 days later with Ni-NTA resin
233 (Qiagen, Hilden, Germany). Proteins were concentrated and buffer exchanged into PBS with
234 Amicon centrifugal filters (Millipore, Burlington, MA) prior to quantification on a
235 spectrophotometer (NanoDrop, Thermo Fisher Scientific, Waltham, MA).

236

237 **ELISAs**

238 Antibodies reactive to SARS-CoV-2 and OC43 antigens were quantified by enzyme-linked
239 immunosorbent assays (ELISA) as previously described^{18,54}. Absorbed sera samples were also
240 tested for the presence of influenza virus H1 HA antibodies. In brief, ELISA plates (Thermo Fisher
241 Scientific, Waltham, MA: cat. 14-245-153) were coated overnight at 4°C with either 2 µg/mL
242 SARS-CoV-2 or influenza HA antigens, 1.5 µg/mL OC43 antigens, or Dulbecco's phosphate
243 buffered saline (DPBS) to control for background antibody binding. Sera was heat-inactivated in
244 a 56°C water bath for 1 hour prior to serial dilutions starting at 1:50 in dilution buffer. ELISA
245 plates were blocked for 1 hour before 50 µL of diluted sera was added and plates were incubated
246 for 2 hours on an orbital shaker. ELISA plates were washed 3 times with 1x PBS supplemented
247 with 2% Tween (PBS-T) before the addition of goat anti-human IgG conjugated to horseradish
248 peroxidase secondary antibody at a 1:5000 dilution (Jackson ImmunoResearch Laboratories, West
249 Grove, PA: cat. 109-036-098). ELISA plates were developed with TMB substrate, and the
250 reactions were stopped after 5 minutes by the addition of 250 mM hydrochloric acid prior to
251 reading on a SpectraMax 190 microplate reader (Molecular Devices, San Jose, CA). Serum
252 antibody titers were obtained from a standard curve of either serially diluted monoclonal antibody
253 (CR3022 for SARS-CoV-2 or CR9114 for influenza virus HA starting at 0.5µg/mL) or serially
254 diluted pooled serum (for OC43 ELISAs). Standard curves were included on every plate to control
255 for plate-to-plate variation. Antibody titers for each sample were measured in at least two technical
256 replicates performed on separate days.

257

258 **Carboxyl magnetic bead absorptions**

259 SARS-CoV-2 FL-S or OC43 FL-S antigens were coupled to carboxyl magnetic beads
260 (RayBiotech, Peachtree Corners, GA; cat. 801-114-2) at a concentration of 35 µg antigen/100 µL
261 magnetic beads. Mock beads were prepared by the addition of DPBS in place of antigen. Briefly,
262 175 µg of diluted antigen or PBS (for mock) was added to 500 µL of magnetic beads and the
263 mixture was incubated for 2 hours at 4°C with constant mixing. The unbound fractions were
264 removed using a magnetic stand and conjugated beads were quenched by the addition of 300 µL
265 50 mM Tris, pH 7.4 prior to a 15-minute incubation at room temperature with constant mixing.
266 Quenching buffer was removed using a magnetic stand and the conjugated beads were washed 4
267 times with 300 µL wash buffer (DPBS supplemented with 0.1% BSA and 0.05% Tween-20). After

268 the final wash, beads were resuspended in 300 μ L wash buffer and were stored at 4°C prior to use
269 in serum absorption assays.

270 Sera samples were absorbed with beads coupled to SARS-CoV-2 FL-S, OC43 FL-S, and
271 mock beads. Sera samples were diluted in PBS to a final dilution of 1:25. Next, 20 μ L of antigen
272 coupled-magnetic beads or mock-treated beads were added to 100 μ L of diluted sera and the
273 mixtures were incubated for 1 hour at room temperature on a plate mixer at 800rpm. Fractions
274 containing the unabsorbed antibodies were removed using a 96-well plate magnetic stand.
275 Unabsorbed fractions were diluted in buffer (DPBS supplemented with 1% milk and 0.1% Tween-
276 20) prior to running in ELISA.

277

278 **QUANTIFICATION AND STATISTICAL ANALYSIS**

279 Statistical analyses were performed using Prism version 8 (GraphPad Software, San Diego CA).
280 Reciprocal serum dilution antibody titers were log₂ transformed for statistical analysis. ELISA
281 antibody titers below the limit of detection (LOD) were set to a reciprocal titer equal to half the
282 LOD. Log₂ transformed antibody titers were compared with paired and unpaired t-tests, and one-
283 way ANOVAs with Tukey's multiple comparisons. Statistical significance was defined as a p-
284 value <0.05.

285

286 **DECLARATION OF INTERESTS**

287 E.J.W. has consulting agreements with and/or is on the scientific advisory board for Merck,
288 Elstar, Janssen, Related Sciences, Synthekine and Surface Oncology. E.J.W. is a founder of
289 Surface Oncology and Arsenal Biosciences. E.J.W. is an inventor on a patent (U.S. patent
290 number 10,370,446) submitted by Emory University that covers the use of PD-1 blockade to
291 treat infections and cancer. S.E.H. has received consultancy fee from Sanofi Pasteur, Lumen,
292 Novavax, and Merck for work unrelated to this report.

293 ACKNOWLEDGEMENTS

294 This project has been funded in part with Federal funds from the National Institute of Allergy
295 and Infectious Diseases, National Institutes of Health, Department of Health and Human
296 Services, under Contract No. 75N93021C00015. This work was supported in part by institutional
297 funds from the University of Pennsylvania and NIH U19AI082630 (S.E.H. and E.J.W.). E.M.A.
298 was supported by the NIH Training in Virology T32 Program (T32-AI-007324). We thank J.
299 Lurie, J. Embiid, J. Harris, and D. Blitzer for philanthropic support. We thank all members of the
300 Penn COVID-19 Sample Processing Unit. We would like to thank David Anderson for assistance
301 with the graphical abstract. The contents of this publication are solely the responsibility of the
302 authors and do not necessarily represent the official views of the NIH.

303 304 AUTHOR CONTRIBUTIONS

305 Serological Assays, E.M.A., T.E., E.C.G, and M.J.B.,
306 Data Analyses, E.M.A.
307 Cohort Studies and Sample Processing, S.G., R.R.G, M.M.P., S.A.A., D.M., D.D., D.F., A.B.,
308 J.W., J.M., S.D., the UPenn COVID Processing Unit, and A.R.G.
309 Manuscript Writing, E.M.A., and S.E.H.;
310 Supervision, I.F., D.J.R, E.J.W., and S.E.H.;
311 Funding Acquisition, I.F., D.J.R, E.J.W., and S.E.H.

312 FIGURE LEGENDS

313 **Figure 1.**
314 **Specificity of SARS-CoV-2 antibodies induced after SARS-CoV-2 infection versus**
315 **vaccination.** ELISAs were completed to quantify levels of serum antibodies binding to the
316 SARS-CoV-2 full-length spike (FL-S) protein, the S1 domain (S1) of S, and the S2 domain (S2)
317 of S after SARS-CoV-2 infection (**A**) and mRNA vaccination (**B**). Paired t-tests of log₂
318 transformed antibody titers ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05. We calculated fold-
319 change in antibody titers before and after seroconversion and pre-/post- prime and boost doses of

320 a SARS-CoV-2 mRNA vaccine (C-E). One way ANOVA of antibody fold change
321 **** $p < 0.0001$, ** $p < 0.01$ * $p < 0.05$. Horizontal lines indicate geometric mean and error bars
322 represent standard deviation.

323

324 **Figure 2.**

325 **Antibodies to a related seasonal coronavirus are boosted upon SARS-CoV-2 infection and**
326 **after vaccination to a lesser extent.** ELISAs were completed to quantify levels of serum
327 antibodies binding to the betacoronavirus, OC43 full-length spike (FL-S) protein, the S1 domain
328 (S1) of S, and the S2 domain (S2) of S after SARS-CoV-2 infection (A) and mRNA vaccination
329 (B). Paired t-tests of log₂ transformed antibody titers **** $p < 0.0001$, *** $p < 0.001$, ** $p < 0.01$,
330 * $p < 0.05$. We calculated fold-change in antibody titers before and after seroconversion and pre-
331 /post- prime and boost doses of a SARS-CoV-2 mRNA vaccine (C-E). One way ANOVA of
332 antibody fold change **** $p < 0.0001$ and *** $p = 0.0001$. Horizontal lines indicate geometric
333 mean and error bars represent standard deviation.

334

335 **Figure 3.**


336 **Seasonal coronavirus spike antibodies boosted by SARS-CoV-2 infection do not bind well**
337 **to SARS-CoV-2 spike.** Sera samples from 10 SARS-CoV-2 infected health care workers (A-C)
338 and 10 SARS-CoV-2 mRNA vaccinated participants (D-F) were absorbed with SARS-CoV-2
339 full length (FL) S-coupled beads, OC43 Full length (FL) S-coupled beads, or mock treated beads
340 prior to antibody quantification by ELISA. We determined reciprocal antibody titers in samples
341 before and after infection and pre-/post- the first dose of an mRNA vaccine for SARS-CoV-2
342 FL-S (A,D), OC43 FL-S (B,E), and an unrelated antigen, influenza hemagglutinin H1 (C, F).
343 Paired t-tests of log₂ transformed antibody titers **** $p < 0.0001$, *** $p < 0.001$, ** $p < 0.01$.


REFERENCES

- 1 Carvalho, T., Krammer, F. & Iwasaki, A. The first 12 months of COVID-19: a timeline of immunological insights. *Nat Rev Immunol* **21**, 245-256, doi:10.1038/s41577-021-00522-1 (2021).
- 2 Zhou, P. *et al.* A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* **579**, 270-273, doi:10.1038/s41586-020-2012-7 (2020).
- 3 Excler, J. L., Saville, M., Berkley, S. & Kim, J. H. Vaccine development for emerging infectious diseases. *Nat Med* **27**, 591-600, doi:10.1038/s41591-021-01301-0 (2021).
- 4 Gebre, M. S. *et al.* Novel approaches for vaccine development. *Cell* **184**, 1589-1603, doi:10.1016/j.cell.2021.02.030 (2021).
- 5 Golob, J. L., Lugogo, N., Luring, A. S. & Lok, A. S. SARS-CoV-2 vaccines: a triumph of science and collaboration. *JCI Insight*, doi:10.1172/jci.insight.149187 (2021).
- 6 Topol, E. J. Messenger RNA vaccines against SARS-CoV-2. *Cell* **184**, 1401, doi:10.1016/j.cell.2020.12.039 (2021).
- 7 Baden, L. R. *et al.* Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med* **384**, 403-416, doi:10.1056/NEJMoa2035389 (2021).
- 8 Polack, F. P. *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* **383**, 2603-2615, doi:10.1056/NEJMoa2034577 (2020).
- 9 Collier, D. A. *et al.* Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. *Nature* **593**, 136-141, doi:10.1038/s41586-021-03412-7 (2021).
- 10 Doria-Rose, N. *et al.* Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. *N Engl J Med* **384**, 2259-2261, doi:10.1056/NEJMc2103916 (2021).
- 11 Liu, Y. *et al.* Neutralizing Activity of BNT162b2-Elicited Serum. *N Engl J Med* **384**, 1466-1468, doi:10.1056/NEJMc2102017 (2021).
- 12 Wang, Z. *et al.* mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. *Nature* **592**, 616-622, doi:10.1038/s41586-021-03324-6 (2021).
- 13 Widge, A. T. *et al.* Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. *N Engl J Med* **384**, 80-82, doi:10.1056/NEJMc2032195 (2021).
- 14 Wu, K. *et al.* Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine. *N Engl J Med* **384**, 1468-1470, doi:10.1056/NEJMc2102179 (2021).
- 15 Wang, Z. *et al.* Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. *Nature* **595**, 426-431, doi:10.1038/s41586-021-03696-9 (2021).
- 16 Gouma, S. *et al.* Health care worker sero-monitoring reveals complex relationships between common coronavirus antibodies and COVID-19 symptom duration. *JCI Insight*, doi:10.1172/jci.insight.150449 (2021).
- 17 Sagar, M. *et al.* Recent endemic coronavirus infection is associated with less-severe COVID-19. *J Clin Invest* **131**, doi:10.1172/JCI143380 (2021).
- 18 Anderson, E. M. *et al.* Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection. *Cell* **184**, 1858-1864 e1810, doi:10.1016/j.cell.2021.02.010 (2021).
- 19 Dijkman, R. *et al.* The dominance of human coronavirus OC43 and NL63 infections in infants. *J Clin Virol* **53**, 135-139, doi:10.1016/j.jcv.2011.11.011 (2012).
- 20 Dyrdak, R., Hodcroft, E. B., Wahlund, M., Neher, R. A. & Albert, J. Interactions between seasonal human coronaviruses and implications for the SARS-CoV-2 pandemic: A


- retrospective study in Stockholm, Sweden, 2009-2020. *J Clin Virol* **136**, 104754, doi:10.1016/j.jcv.2021.104754 (2021).
- 21 Gaunt, E. R., Hardie, A., Claas, E. C., Simmonds, P. & Templeton, K. E. Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method. *J Clin Microbiol* **48**, 2940-2947, doi:10.1128/JCM.00636-10 (2010).
- 22 Huang, A. T. *et al.* A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. *Nat Commun* **11**, 4704, doi:10.1038/s41467-020-18450-4 (2020).
- 23 Killerby, M. E. *et al.* Human coronavirus circulation in the United States 2014-2017. *J Clin Virol* **101**, 52-56, doi:10.1016/j.jcv.2018.01.019 (2018).
- 24 Edridge, A. W. D. *et al.* Seasonal coronavirus protective immunity is short-lasting. *Nat Med* **26**, 1691-1693, doi:10.1038/s41591-020-1083-1 (2020).
- 25 Eguia, R. T. *et al.* A human coronavirus evolves antigenically to escape antibody immunity. *PLoS Pathog* **17**, e1009453, doi:10.1371/journal.ppat.1009453 (2021).
- 26 Kistler, K. E. & Bedford, T. Evidence for adaptive evolution in the receptor-binding domain of seasonal coronaviruses OC43 and 229e. *Elife* **10**, doi:10.7554/eLife.64509 (2021).
- 27 Jaimes, J. A., Andre, N. M., Chappie, J. S., Millet, J. K. & Whittaker, G. R. Phylogenetic Analysis and Structural Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary Distinct and Proteolytically Sensitive Activation Loop. *J Mol Biol* **432**, 3309-3325, doi:10.1016/j.jmb.2020.04.009 (2020).
- 28 Okba, N. M. A. *et al.* Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients. *Emerg Infect Dis* **26**, 1478-1488, doi:10.3201/eid2607.200841 (2020).
- 29 Andersen, K. G., Rambaut, A., Lipkin, W. I., Holmes, E. C. & Garry, R. F. The proximal origin of SARS-CoV-2. *Nat Med* **26**, 450-452, doi:10.1038/s41591-020-0820-9 (2020).
- 30 Boni, M. F. *et al.* Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic. *Nat Microbiol* **5**, 1408-1417, doi:10.1038/s41564-020-0771-4 (2020).
- 31 Ng, K. W. *et al.* Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. *Science* **370**, 1339-1343, doi:10.1126/science.abe1107 (2020).
- 32 Song, G. *et al.* Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection. *Nat Commun* **12**, 2938, doi:10.1038/s41467-021-23074-3 (2021).
- 33 Nguyen-Contant, P. *et al.* S Protein-Reactive IgG and Memory B Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2 Subunit. *mBio* **11**, doi:10.1128/mBio.01991-20 (2020).
- 34 Jackson, L. A. *et al.* An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. *N Engl J Med* **383**, 1920-1931, doi:10.1056/NEJMoa2022483 (2020).
- 35 Roltgen, K. *et al.* mRNA vaccination compared to infection elicits an IgG-predominant response with greater SARS-CoV-2 specificity and similar decrease in variant spike recognition. *medRxiv*, doi:10.1101/2021.04.05.21254952 (2021).
- 36 Amanat, F. *et al.* SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. *Cell* **184**, 3936-3948 e3910, doi:10.1016/j.cell.2021.06.005 (2021).

- 37 McNaughton, A. L. *et al.* Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses. *medRxiv*, 2021.2005.2004.21256571, doi:10.1101/2021.05.04.21256571 (2021).
- 38 Francis, T. On the Doctrine of Original Antigenic Sin. *Proceedings of the American Philosophical Society* **104**, 572-578 (1960).
- 39 Arevalo, C. P. *et al.* Original antigenic sin priming of influenza virus hemagglutinin stalk antibodies. *Proc Natl Acad Sci U S A* **117**, 17221-17227, doi:10.1073/pnas.1920321117 (2020).
- 40 Goel, R. R. *et al.* Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals following mRNA vaccination. *Sci Immunol* **6**, doi:10.1126/sciimmunol.abi6950 (2021).
- 41 Lombardi, A. *et al.* Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results. *Front Immunol* **12**, 657711, doi:10.3389/fimmu.2021.657711 (2021).
- 42 Barnes, C. O. *et al.* Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. *Cell* **182**, 828-842 e816, doi:10.1016/j.cell.2020.06.025 (2020).
- 43 Letko, M., Marzi, A. & Munster, V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. *Nat Microbiol* **5**, 562-569, doi:10.1038/s41564-020-0688-y (2020).
- 44 Walls, A. C. *et al.* Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. *Cell* **181**, 281-292 e286, doi:10.1016/j.cell.2020.02.058 (2020).
- 45 Wrapp, D. *et al.* Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science* **367**, 1260-1263, doi:10.1126/science.abb2507 (2020).
- 46 Greaney, A. J. *et al.* Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection. *Sci Transl Med* **13**, doi:10.1126/scitranslmed.abi9915 (2021).
- 47 Starr, T. N. *et al.* SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. *Nature*, doi:10.1038/s41586-021-03807-6 (2021).
- 48 Stamatatos, L. *et al.* mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. *Science*, doi:10.1126/science.abg9175 (2021).
- 49 Planas, D. *et al.* Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. *Nature*, doi:10.1038/s41586-021-03777-9 (2021).
- 50 Turner, J. S. *et al.* SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. *Nature* **596**, 109-113, doi:10.1038/s41586-021-03738-2 (2021).
- 51 Brewer, R. C., Ramadoss, N. S., Lahey, L. J., Robinson, W. H. & Lanz, T. V. BNT162b2 Vaccine Induces Divergent B cell responses to SARS-CoV-2 S1 and S2. *medRxiv*, 2021.2007.2020.21260822, doi:10.1101/2021.07.20.21260822 (2021).
- 52 Cobey, S. & Hensley, S. E. Immune history and influenza virus susceptibility. *Curr Opin Virol* **22**, 105-111, doi:10.1016/j.coviro.2016.12.004 (2017).
- 53 Amanat, F. *et al.* A serological assay to detect SARS-CoV-2 seroconversion in humans. *Nat Med*, doi:10.1038/s41591-020-0913-5 (2020).
- 54 Flannery, D. D. *et al.* SARS-CoV-2 seroprevalence among parturient women in Philadelphia. *Sci Immunol* **5**, doi:10.1126/sciimmunol.abd5709 (2020).






antibodies elicited by infection



antibodies elicited by vaccination



Supplemental Table 1

	Infection	Vaccination	p-value
Total (N)	10	23	
Median Age in years [min-max]	35 [25-49]	38 [23-67]	0.8735
Number of Female [%]	8 [80%]	15 [65%]	0.6822